基于常规医院数据集推导的肺癌患者合并症评分的国际可比性研究
结果显示三种评分在各辖区均可生成且内容、表面和同时效度良好,但预测效度有限、可靠性存疑,记录的合并症跨辖区可比性受编码和入院实践差异限制。
要点
- 三种合并症评分可在各ICBP辖区从常规医院数据集推导生成
- 评分内容、表面和同时效度良好,但预测效度有限且可靠性存疑
- 跨辖区合并症记录可比性受限,需国际统一的合并症指数
核心结论
- 记录的合并症跨辖区可比性有限,可能源于各区域编码和入院实践的差异。
- 在探讨合并症对癌症生存国际差异的贡献前,需要建立国际统一的合并症指数。
研究设计与样本
- 对每例患者基于肺癌诊断前4-36个月数据推导Charlson、Elixhauser和住院床日三种合并症评分。
- 比较各评分以评估其在国际生存比较中的效度和可行性。
主要发现
- 各辖区均能生成三种合并症评分,评分具有良好内容效度、表面效度和同时效度。
- 预测效度有限,且有证据表明可靠性存疑。
临床怎么用
- 利用常规医院数据集推导的合并症评分进行国际生存比较时,需考虑编码和入院实践差异的影响。
- 在建立国际统一合并症指数前,不宜直接以现有评分量化合并症对肺癌生存国际差异的影响。
局限性
- 预测效度有限且可靠性存疑。
- 各辖区编码和医院入院实践可能存在差异,影响合并症记录的跨辖区可比性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The International Cancer Benchmarking Partnership (ICBP) identified significant international differences in lung cancer survival. Differing levels of comorbid disease across ICBP countries has been suggested as a potential explanation of this variation but, to date, no studies have quantified its impact. This study investigated whether comparable, robust comorbidity scores can be derived from the different routine population-based cancer data sets available in the ICBP jurisdictions and, if so, use them to quantify international variation in comorbidity and determine its influence on outcome. METHODS: Linked population-based lung cancer registry and hospital discharge data sets were acquired from nine ICBP jurisdictions in Australia, Canada, Norway and the UK providing a study population of 233 981 individuals. For each person in this cohort Charlson, Elixhauser and inpatient bed day Comorbidity Scores were derived relating to the 4-36 months prior to their lung cancer diagnosis. The scores were then compared to assess their validity and feasibility of use in international survival comparisons. RESULTS: It was feasible to generate the three comorbidity scores for each jurisdiction, which were found to have good content, face and concurrent validity. Predictive validity was limited and there was evidence that the reliability was questionable. CONCLUSION: The results presented here indicate that interjurisdictional comparability of recorded comorbidity was limited due to probable differences in coding and hospital admission practices in each area. Before the contribution of comorbidity on international differences in cancer survival can be investigated an internationally harmonised comorbidity index is required.
引用
- Lüchtenborg M, Morris EJA, Tataru D, et al. Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer. Thorax. 2017. PMID: 29079609. doi:10.1136/thoraxjnl-2017-210362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。